Compare SDSTW & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDSTW | ENVB |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.0M |
| IPO Year | N/A | N/A |
| Metric | SDSTW | ENVB |
|---|---|---|
| Price | $0.13 | $5.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 41.6K | ★ 55.5K |
| Earning Date | 03-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $4.88 |
| 52 Week High | $0.12 | $96.30 |
| Indicator | SDSTW | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 60.24 |
| Support Level | $0.17 | $5.47 |
| Resistance Level | $0.17 | $6.10 |
| Average True Range (ATR) | 0.02 | 0.48 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 7.14 | 61.53 |
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.